research Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases
Ixekizumab has known and some unexpected side effects.
Search
for
Sort by
Research
240-270 / 1000+ results
research TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris
Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.
research Recalcitrant lichen planopilaris treated with upadacitinib: a case series
Upadacitinib may effectively treat resistant lichen planopilaris.
research Ritlecitinib in severe alopecia areata: a profile of its use
Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
research Teriflunomide efficacy, safety and tolerability in patients with relapsing forms of multiple sclerosis
Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
research Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study
GLP-1 RA medications may be linked to hair loss.
research FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
Deuruxolitinib is FDA-approved for treating severe alopecia areata.
research Linagliptin-Associated Alopecia and Bullous Pemphigoid
Linagliptin may cause hair loss and skin blisters.
research Supplementary file 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx
Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
research Upadacitinib is effective in treating psoriasis combined with lichen planus: a case report
Upadacitinib effectively treats psoriasis and lichen planus together.
research JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
Deuruxolitinib effectively promotes hair regrowth in alopecia areata.
research Efficacy and Safety of Vildagliptin and Remogliflozin as Add-on Therapy to Metformin in Patients of Type 2 Diabetes Mellitus
research Lichen planopilaris treated with thalidomide
Thalidomide significantly improved hair regrowth in a woman with lichen planopilaris.
research FERTILITY-SPARING MANAGEMENT OF ENDOMETRIAL INTRAEPITHELIAL NEOPLASIA & ENDOMETRIAL CANCER: A COMPARISON OF THE LEVONORGESTREL-RELEASING INTRAUTERINE DEVICE VS SYSTEMIC THERAPY
Both LNG-IUD and systemic progestins are effective for fertility-sparing treatment, but close monitoring is needed due to recurrence risk.
research Table 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx
Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
research S3886 Concurrent Management of Crohn's Ileitis and Alopecia Universalis With Upadacitinib
Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.
research AB0326 REAL-WORLD EXPERIENCE ON SWITCHING ADALIMUMAB ORIGINATOR TO BIOSIMILAR IN INFLAMMATORY ARTHRITIS – A RETROSPECTIVE STUDY
Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.
research La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
research Treatment of insulin resistance with tirzepatide leading to improvement of hair loss
Tirzepatide may improve hair loss by reducing insulin resistance.
research Suspected upadacitinib-associated drug hypersensitivity mimicking disease exacerbation in ulcerative colitis
Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.
research Ruxolitinib Rescues Multiorgan Clinical Autoimmunity in Patients with APS-1
Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
research Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.
research Severe steroid-dependent idiopathic angioedema with response to rituximab
A woman with severe angioedema improved significantly after treatment with rituximab.
research ANIFROLUMAB IN THE MANAGEMENT OF LUPUS HEADACHES: A CASE REPORT
Anifrolumab effectively improved lupus headaches in a patient unresponsive to other treatments.
research Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite
Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
research Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study.
Leuprolide plus estrogen is more effective than oral contraceptives for reducing hirsutism.
research Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
research Alopecia secondary to severe discoid lupus responding to anifrolumab
Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.
research Immune globulin
Two men experienced hair regrowth while being treated with immune globulin for other health issues, but there were also side effects.